GlassScriptPhysician profile
Daniel Maksimovich
NPI 1932450285
$380.64
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $50.53 · 2021: $64.21 · 2022: $109 · 2023: $133 · 2024: $24.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $157.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Trevena, INC. | $87.33 | 2023-2024 | Olinvyk |
| Kowa Pharmaceuticals America, INC. | $46.20 | 2023 | Seglentis |
| Spineology INC. | $34.79 | 2020 | |
| Baudax Bio INC. | $29.74 | 2021-2022 | |
| Axonics, INC. | $24.84 | 2022 | |
| Integra Lifesciences Corporation | $23.83 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Takeda Pharmaceuticals U.S.A., INC. | $19.33 | 2022 | |
| Heron Therapeutics, INC. | $19.04 | 2022 | |
| Vivus LLC | $18.74 | 2022 | |
| Redhill Biopharma INC. | $17.31 | 2021 | |
| Acacia Pharma INC | $16.16 | 2021 | |
| Allergan, INC. | $15.80 | 2021 | |
| Amgen INC. | $15.74 | 2020 | |
| Polynovo North America LLC | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Maksimovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.